Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Roquefort Investments PLC ( (GB:ROQ) ) is now available.
Roquefort Therapeutics PLC has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd, potentially earning up to $25 million in milestone payments and a royalty on sales. This strategic move is part of a broader group restructuring, which includes the sale of its subsidiary Lyramid Pty Ltd to Pleiades, contingent on successful fundraising. The restructuring aims to benefit existing shareholders and allow Roquefort to focus on a transformative acquisition with A2A Pharmaceuticals and Coiled Therapeutics, enhancing its position in the biotech industry.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market of the London Stock Exchange. The company is focused on acquiring exclusive license rights to AO-252, a novel drug targeting the TACC3 protein for cancer treatment. Roquefort Therapeutics is also involved in the development of the MK Cell program and the STAT-6 program.
Average Trading Volume: 2,022,137
Technical Sentiment Signal: Sell
Current Market Cap: £2.91M
Learn more about ROQ stock on TipRanks’ Stock Analysis page.